Brickell Stock Valuation

BBI
 Stock
  

USD 0.10  0.03  23.08%   

Do you want to know what the current value of Brickell Biotech is today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Brickell Biotech, is its stock price multiplied by the total number of shares outstanding, calculating Brickell Biotech's enterprise value requires a different approach. It uses Brickell Biotech's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Brickell Biotech Enterprise Value is most likely to decrease significantly in the upcoming years. The preceding year's Enterprise Value was reported at 4.97 Million. The current Tangible Asset Value is estimated to increase to about 36.7 M, while Free Cash Flow is projected to decrease to (37.1 M).
Brickell Biotech seems to be undervalued based on Macroaxis valuation methodology. Our model approximates the value of Brickell Biotech from analyzing the firm fundamentals such as Return On Equity of (151.70) %, shares owned by insiders of 1.31 %, and Current Valuation of (1.75 M) as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor locking in undervalued instruments and disposing overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
  
Refresh
Brickell Biotech Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Brickell Biotech's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Brickell Most Recent Valuation Data

Price Book
0.91
Price Sales
24.43
EBITDA
-40.6 M
Beta
0.3
Fiscal Year End
December
Industry
Biotechnology
Enterprise Value
-2.7 M
Undervalued
Today 0.10
Please note that Brickell Biotech's price fluctuation is out of control at this time. Calculation of the real value of Brickell Biotech is based on 3 months time horizon. Increasing Brickell Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Brickell Biotech is useful when determining the fair value of the Brickell stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Brickell Biotech. Since Brickell Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Brickell Stock. However, Brickell Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
1.07
Real Value
10.93
Upside
Estimating the potential upside or downside of Brickell Biotech helps investors to forecast how Brickell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Brickell Biotech more accurately as focusing exclusively on Brickell Biotech's fundamentals will not take into account other important factors:
Earnings
Estimates (1)
LowProjected EPSHigh
-0.53-0.53-0.53
Details
Hype
Prediction
LowEstimated ValueHigh
0.010.109.96
Details
Naive
Forecast
LowNext ValueHigh
0.0024570.129.98
Details
1 Analysts
Consensus
LowTarget PriceHigh
4.004.004.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Brickell Biotech's intrinsic value based on its ongoing forecasts of Brickell Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Brickell Biotech's closest peers. When choosing an evaluation method for Brickell Biotech, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Brickell Biotech Investments

4.15 Million

Share

Brickell Valuation Drivers Correlation

Many accounts on the financial statements of Brickell Biotech are highly interrelated and sometimes correlated. Consequently, when conducting Brickell's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Brickell
Click cells to compare fundamentals

Brickell Valuation Trend

Knowing Brickell Biotech's actual value is paramount for traders to make sound investment determinations. Brickell Biotech's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Brickell Biotech's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Brickell Biotech's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Brickell Biotech Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Brickell Biotech's current stock value. Our valuation model uses many indicators to compare Brickell Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Brickell Biotech competition to find correlations between indicators driving Brickell Biotech's intrinsic value. More Info.
Brickell Biotech is rated below average in beta category among related companies. It is rated below average in price to book category among related companies fabricating about  4.00  of Price to Book per Beta. The current Price to Book Value is estimated to increase to 1.21. Comparative valuation analysis is a catch-all model that can be used if you cannot value Brickell Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Brickell Biotech's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Brickell Biotech's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Brickell Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Brickell Biotech and how it compares across the competition.

About Brickell Biotech Valuation

The equity valuation mechanism determines the current worth of Brickell Biotech on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Brickell Biotech. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Brickell Biotech based exclusively on its fundamental and basic technical indicators. By analyzing Brickell Biotech's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Brickell Biotech's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Brickell Biotech. We calculate exposure to Brickell Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Brickell Biotech's related companies.
Last ReportedProjected for 2022
Gross Profit404 K414.6 K
Profit Margin(97.71) (100.28) 
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Brickell Biotech Quarterly Enterprise Value

5.05 Million

Share

Brickell Biotech Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Brickell Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio5.59
Revenue Growth285.20%
Enterprise Value To Ebitda0.04
Enterprise Value To Revenue-4.32

Brickell Biotech Current Valuation Indicators

Valuation refers to the process of determining the present value of Brickell Biotech and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Brickell we look at many different elements of the entity such as Brickell's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Brickell Biotech's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Brickell Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Brickell Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Brickell Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Brickell Biotech's worth.
Continue to Trending Equities. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
11.7 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.